Gene Express Names Michael Rowe Worldwide Marketing VP Gene Express Inc, Toledo, Ohio, has named Michael M.Rowe as senior VP of global marketing.
Rowe will oversee the companys worldwide marketing campaign and strategies.
With his 25 years of experience in pharmaceuticals, biologics, and...
Gene Express, Inc.: Gene Express Appoints Michael Rowe to Senior VP of Global Marketing - Gene Express, Inc.today announced the appointment of Michael M.
Rowe, to Senior Vice President of Global Marketing.
Gerald Vardzel, CEO of Gene Express, commented, 'We are pleased to have Michael join our team.
Michael will be...
Gene Express Appoints Michael Rowe to Senior VP of Global Marketing TOLEDO, OH -- (MARKET WIRE) -- 06/12/08 -- Gene Express, Inc.today announced the appointment of Michael M.
Rowe, to Senior Vice President of Global Marketing.
Gerald Vardzel, CEO of Gene Express, commented, 'We are pleased to have...
Gene Express Appoints Michael Rowe to Senior VP of Global Marketing - Gene Express, Inc.today announced the appointment of Michael M.
Rowe, to Senior Vice President of Global Marketing.
Gerald Vardzel, CEO of Gene Express, commented, 'We are pleased to have Michael join our team.
Michael will be...
Gene Express Appoints Michael Rowe to Senior VP of Global Marketing -- Gene Express, Inc.today announced the appointment of Michael M.
Rowe, to Senior Vice President of Global Marketing.
Gerald Vardzel, CEO of Gene Express, commented, 'We are pleased to have Michael join our team.
Michael will be...
Gene Express Appoints Michael Rowe to Senior VP of Global Marketing Gene Express, Inc.today announced the appointment of Michael M.
Rowe, to Senior Vice President of Global Marketing.
Gerald Vardzel, CEO of Gene Express, commented, 'We are pleased to have Michael join our team.
Michael will be...
Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen, New Survey Reveals DENVER, May 28 /PRNewswire/ -- Nearly all people (97 percent) with multiple sclerosis (MS) who have started treatment say their commitment to managing their disease in every way possible is their prime motivation for staying on therapy,...
A Strange Novartis MS Drug Story Swiss drugmaker Novartis (NYSE: NVS) announced that it had received European Union marketing approval for its version of a multiple sclerosis (MS) drug that has long been marketed by Bayer.The drug in question is Bayer's MS interferon...
Novartis' MS drug gets approval in EU ZURICH (Reuters) - Swiss drugmaker Novartis said on Monday its Extavia multiple sclerosis drug had been approved in the European Union and repeated that it planned to launch Extavia in the U.S.and Europe in the first half of 2009.
The...
Novartis' MS drug gets approval in EU ZURICH (Reuters) - Swiss drugmakerNovartis said on Monday its Extavia multiple sclerosis drug had been approved in the European Union and repeated that it planned to launch Extavia in the U.S.and Europe in the first half of 2009.
The...
Novartis' MS drug Extavia gains approval in EU Swiss drugmaker Novartis AG announced Monday that the European Commission has approved its multiple sclerosis drug Extavia for the treatment of early and relapsing forms of multiple sclerosis (MS).The multinational pharmaceutical group...
Novartis' MS drug gets approval in EU ZURICH (Reuters) - Swiss drugmakerNovartis said on Monday its Extavia multiple sclerosis drug had been approved in the European Union and repeated that it planned to launch Extavia in the U.S.and Europe in the first half of 2009.
The...
Novartis wins European approval for multiple sclerosis drug Extavia is the Novartis branded version of interferon beta-1b, a first-line disease-modifying therapy injected every other day for the treatment of multiple sclerosis (MS).Formerly known as NVF233, Extavia is the same medicine as...
Novartis Wins European Approval for Multiple Sclerosis Drug Novartis has announced that the European Commission has approved Extavia for the treatment of early and relapsing forms of multiple sclerosis.The drug is said to be the first in a new portfolio of medicines from Novartis that is planned...
Novartis wins European approval for multiple sclerosis drug Novartis has announced that the European Commission has approved Extavia for the treatment of early and relapsing forms of multiple sclerosis.The drug is said to be the first in a new portfolio of medicines from Novartis that is planned...
Staying in the Game According to Ken Liss, national sales director of specialized therapeutics at Bayer, 'We were seeking a fresh way to help our specialized therapeutics sales representatives apply the in-depth information they learn about Betaseron and...
